NASDAQ:TLC

Taiwan Liposome (TLC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$7.00
$7.09
50-Day Range
$6.76
$7.63
52-Week Range
$4.07
$7.70
Volume
12,421 shs
Average Volume
133,095 shs
Market Capitalization
$294.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TLC stock logo

About Taiwan Liposome Stock (NASDAQ:TLC)

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.

TLC Stock News Headlines

Urgent Nvidia Warning
Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.
Urgent Nvidia Warning
Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.
See More Headlines
Receive TLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/28/2020
Today
4/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLC
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Net Income
$-35,020,000.00
Net Margins
-299.27%
Pretax Margin
-306.10%

Debt

Sales & Book Value

Annual Sales
$3.63 million
Book Value
$0.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$294.54 million
Optionable
Not Optionable
Beta
0.99
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Kee Lung Hong
    Chairman & Chief Executive Officer
  • Chih Hung Yeh
    President & General Manager
  • Yi Ju Chen
    Head-Finance & Accounting
  • Yun Lung Tseng
    Deputy General Manager-Research & Development
  • George Spencer-Green
    Chief Medical Officer

TLC Stock Analysis - Frequently Asked Questions

How were Taiwan Liposome's earnings last quarter?

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) released its quarterly earnings data on Wednesday, October, 28th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.06. The business had revenue of $2.28 million for the quarter, compared to analyst estimates of $0.38 million. Taiwan Liposome had a negative trailing twelve-month return on equity of 120.45% and a negative net margin of 299.27%.

What other stocks do shareholders of Taiwan Liposome own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taiwan Liposome investors own include Gilead Sciences (GILD), Pfizer (PFE), Wells Fargo & Company (WFC), Agnico Eagle Mines (AEM), Applied Genetic Technologies (AGTC), Celldex Therapeutics (CLDX), Seabridge Gold (SA), Trevena (TRVN), AbbVie (ABBV) and Advanced Micro Devices (AMD).

When did Taiwan Liposome IPO?

Taiwan Liposome (TLC) raised $29 million in an initial public offering on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor served as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

This page (NASDAQ:TLC) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners